On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach

Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials

J I Johnson, Shannon Decker, Daniel Zaharevitz et al. · British Journal of Cancer · 2001 · 850 citations · Full text

Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy

Howard A. Burris, Hope S. Rugo, Svetislava J. Vukelja et al. · Journal of Clinical Oncology · 2010 · 758 citations · Full text

Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer

Ian E. Krop, Muralidhar Beeram, Shanu Modi et al. · Journal of Clinical Oncology · 2010 · 590 citations

Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models.

Theodora Voskoglou-Nomikos, Joseph L. Pater, Lesley Seymour · PubMed · 2003 · 523 citations

Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery:  Effects of Linker Technology on Efficacy and Toxicity

Svetlana O. Doronina, Brian A. Mendelsohn, Tim D. Bovee et al. · Bioconjugate Chemistry · 2005 · 506 citations

Mab Degradation, Immunology, Immunotherapy +19